Article Text

Download PDFPDF
Where next for cell-based therapy in ARDS

Statistics from Altmetric.com

Footnotes

  • Contributors AJB wrote the initial draft, and CMO and DFM edited and completed the final version.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests AJB declares no competing interest. DFM’s institution has received a grant from the Wellcome Trust for a clinical trial of MSCs in ARDS. Outside of the submitted work, DFM reports personal fees from consultancy for GlaxoSmithKline, SOBI, Peptinnovate, Boehringer Ingelheim and Bayer, funds to his institution from grants from the UK NIHR and others and from GlaxoSmithKline for undertaking bronchoscopy as part of a clinical trial. In addition, DFM has a patent application issued to his institution. CMO’s institution has received a grant from the Wellcome Trust for a clinical trial of MSCs in ARDS. Outside of the submitted work CMO reports that her spouse has received personal fees from consultancy for GlaxoSmithKline, SOBI, Peptinnovate, Boehringer Ingelheim and Bayer. CMO’s institution has also received funds from grants from the Northern Ireland Health and Social Care Research and Development office.

  • Patient consent Not required.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles